Natera, Inc. ($NTRA) Stock Forecast: Up 17.2% Today

What is Natera, Inc.?

Natera, Inc. (NTRA) is a company listed on the NASDAQ exchange. It reported better-than-expected third-quarter financial results and provided upbeat guidance for future revenues.

Why is Natera, Inc. going up?

NTRA stock is up 17.2% on Nov 13, 2024 19:43

• Natera (NTRA) stock experienced a strong bullish movement following the release of its third-quarter financial results.
• Analysts increased their forecasts for Natera after the company reported a quarterly loss that was lower than expected and topped revenue estimates.
• The options market also indicated a bullish sentiment towards Natera, with significant funds taking a positive position in the company.
• The positive performance of Natera stock could be attributed to the company's strong financial results and optimistic revenue guidance for the future, leading to increased investor confidence and driving the stock price higher.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera Analysts Increase Their Forecasts Following Upbeat Results - Natera ( NASDAQ:NTRA )

Natera, Inc. NTRA reported better-than-expected third-quarter financial results and issued FY24 revenue guidance above estimates on Tuesday. Natera reported a quarterly loss of 26 cents per share, which beat the analyst consensus estimate of a loss of 58 cents per share .

https://www.benzinga.com/24/11/41950428/natera-analysts-increase-their-forecasts-following-upbeat-results

Natera ( NTRA ) Reports Q3 Loss, Tops Revenue Estimates

Natera (NTRA) delivered earnings and revenue surprises of 54.39% and 21.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2369264/natera-ntra-reports-q3-loss-tops-revenue-estimates

What the Options Market Tells Us About Natera - Natera ( NASDAQ:NTRA )

Investors with significant funds have taken a bullish position in Natera NTRA, a development that retail traders should be aware of. This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga.

https://www.benzinga.com/insights/options/24/11/41881596/what-the-options-market-tells-us-about-natera

HealthEquity ( HQY ) Moves 9.8% Higher: Will This Strength Last?

HealthEquity (HQY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

https://www.zacks.com/stock/news/2366105/healthequity-hqy-moves-98-higher-will-this-strength-last

Trending Today

Optimism ($OP) Crypto Forecast: Up 5.6% Today

XRP ($XRP) Crypto Forecast: Up 17.4% Today

NEAR Protocol ($NEAR) Crypto Forecast: Up 5.2% Today

Polkadot ($DOT) Crypto Forecast: Up 9.1% Today

Bonk ($BONK) Crypto Forecast: Down 8.3% Today

Stellar ($XLM) Crypto Forecast: Up 35.1% Today

Cardano ($ADA) Crypto Forecast: Up 22.7% Today

Ethena ($ENA) Crypto Forecast: Up 5.4% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.6% Today

The Graph ($GRT) Crypto Forecast: Up 5.9% Today

Natera, Inc. Price History

13.10.2024 - NTRA Stock was up 15.7%

• Natera (NTRA) reported a Q3 loss but exceeded revenue estimates, which may have positively influenced investor sentiment.
• The bullish position taken by investors in the options market indicates confidence in Natera's future performance.
• The combination of beating revenue estimates and positive investor sentiment from the options market likely contributed to the strong bullish movement in Natera's stock today.

19.06.2024 - NTRA Stock was down 5.1%

• The CEO selling over $600k in company stock might have signaled a lack of confidence in the company's future prospects, leading to a bearish sentiment among investors.
• Despite Natera's strong historical performance outperforming the market over the past 5 years, the recent insider selling could have eroded investor trust in the company's growth potential.
• The market may be reacting negatively to the CEO's decision to offload a substantial amount of company stock, causing a sell-off and driving the stock price down significantly today.

13.10.2024 - NTRA Stock was up 17.2%

• Natera (NTRA) stock experienced a strong bullish movement following the release of its third-quarter financial results.
• Analysts increased their forecasts for Natera after the company reported a quarterly loss that was lower than expected and topped revenue estimates.
• The options market also indicated a bullish sentiment towards Natera, with significant funds taking a positive position in the company.
• The positive performance of Natera stock could be attributed to the company's strong financial results and optimistic revenue guidance for the future, leading to increased investor confidence and driving the stock price higher.

05.05.2024 - NTRA Stock was up 5.2%

• Natera (NTRA) saw a strong bullish movement in the market recently.
• This positive trend is linked to Natera's upgraded initial 2024 guidance in Q1, pointing towards promising growth opportunities ahead.
• Some initial market uncertainty arose from the selling of shares by directors Gail Marcus and Rowan Chapman. However, the overall positive market outlook and raised guidance overshadowed these concerns.
• The decrease in short interest in Natera also played a role in the upward movement, reflecting a decline in bearish sentiment among investors.

10.04.2024 - NTRA Stock was up 11.9%

• Natera's stock reached a three-year peak post strong first-quarter earnings that exceeded market forecasts.
• The market's upbeat attitude towards Natera may stem from the increasing importance of genomics in healthcare, with Natera leading the way in uncovering genetic insights for better health outcomes.
• Natera's stock rally could also be linked to the general market optimism, as seen with other genomics companies posting significant gains.
• Investors are eyeing Natera for its strong performance and growth prospects in the expanding genomics market, expected to see substantial growth by 2033.

25.03.2024 - NTRA Stock was down 5.1%

• StockNews.com downgraded the stock to a sell rating, potentially influencing investor sentiment negatively.
• Natera's chief legal officer engaged in stock transactions, while the company's CFO and president of clinical diagnostics sold company stock, which may have impacted the bearish movement.
• The market's view of Natera might have been influenced by insider selling activities, leading to a decline in the stock price.
• Despite promising developments in the oncology market, internal selling within Natera appears to have outweighed positive aspects, resulting in the stock's bearish movement.

10.04.2024 - NTRA Stock was up 12.3%

• Natera's stock saw a strong bullish movement today, rising significantly in pre-market trading.
• The surge in Natera's stock price can be attributed to the company's strong first-quarter earnings report, where they outperformed market expectations with a lower-than-expected GAAP loss per share and higher-than-anticipated quarterly sales.
• The positive earnings report showcases Natera's continued growth and success in the genomics industry, positioning them as a key player in unlocking the potential of genetic testing and personalized medicine.
• The revelation of Natera's CFO selling over $175k in company stock might have raised some eyebrows, but it did not seem to deter investors who were impressed by the company's financial performance and growth prospects.

18.06.2024 - NTRA Stock was down 5.2%

• The bearish movement in Natera's stock could be attributed to the CEO selling over $600k in company stock.
• Investors may interpret the CEO's decision to sell a substantial amount of company stock as a lack of faith in the company's potential for growth or profitability in the near term.
• The market's reaction to the CEO's stock sale could indicate a loss of confidence among investors leading to a sell-off of Natera's shares and contributing to the bearish movement in the stock price today.

30.06.2024 - NTRA Stock was down 5.2%

• The bearish movement in NTRA stock could be attributed to the CFO and the president of clinical diagnostics selling significant amounts of company shares, possibly raising concerns among investors about the company's future performance.
• Despite the positive news about the validation of Natera's Signatera test for Merkel Cell Carcinoma, the focus on insider selling might have overshadowed the positive developments in the company.
• Investors might be cautious about the upcoming earnings report, even though Natera is expected to beat earnings estimates. The uncertainty surrounding the stock could have led to profit-taking and contributed to the bearish movement.
• The market might be reacting to the overall selling pressure from company insiders, leading to a negative sentiment towards Natera's stock despite the promising clinical utility of their products.

06.07.2024 - NTRA Stock was up 5.5%

• Participation in a growth conference likely sparked investor interest and confidence in the company's future prospects.
• A presentation by the leadership team may have highlighted innovative strategies and growth opportunities, leading to increased optimism among investors.
• The availability of a live webcast could have provided further insights into advancements in cell-free DNA testing, potentially attracting more attention from the investment community.

07.07.2024 - NTRA Stock was up 6.3%

• Natera has outperformed the market significantly over the past 5 years, showcasing strong growth prospects and investor confidence.
• The company's participation in the Canaccord Genuity 44th Annual Growth Conference likely generated positive investor sentiment and highlighted Natera's strategic initiatives and future growth prospects.
• The live webcast of the event provided investors with an opportunity to gain insights into Natera's advancements in cell-free DNA testing, potentially driving further interest and investment in the company.

09.07.2024 - NTRA Stock was up 6.8%

• Natera reported a Q2 loss but surpassed revenue estimates, indicating strong performance and potential growth prospects.
• The stock has outperformed the market over the past 5 years, showcasing consistent growth and investor confidence.
• Participation in the Canaccord Genuity 44th Annual Growth Conference suggests Natera's commitment to showcasing its strategies and growth prospects, which might have positively influenced investor sentiment.
• Overall, the combination of positive financial results, long-term market outperformance, and active participation in industry events likely contributed to the bullish movement in Natera's stock today.